Received: 21 May 2019
Accepted: 23 September 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: The study was approved by the Regional Ethics Committee of Eastern Norway ref. 2011/1339, the Norwegian Medicines Agency and the Norwegian Data Inspectorate. All patients provided written, informed consent before inclusion.
: Not applicable.
: JG Roche; GLG Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Eli Lilly, Novartis, Pfizer, MSD, Roche; UCB and SWS Roche; EKS Pfizer; TKK AbbVie, Biogen, Celltrion, Egis, Eli Lilly, Hospira, MSD, Mylan, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandoz, Sanofi; UCB, BMS and NB Pfizer, Orion Pharma, Napp pharmaceuticals, Takeda, Roche, Janssen, Novartis.The remaining authors declare that they have no competing interests. Disclosures listed above include fees for speaking and/or consulting or research funding to the institution (Diakonhjemmet Hospital).